

High-Dose Rybelsus Trial Results Show Greater A1C and Weight Reduction in...
Novo Nordisk’s PIONEER PLUS trial has delivered promising A1C and weight loss results for patients with type 2 diabetes taking the oral semaglutide Rybelsus at significantly higher doses. Continue Reading